NEWTOWN, Pa., Nov. 12, 2013 /PRNewswire/ -- BioClinica®, Inc., a global clinical research organization specializing in technology-enhanced solutions for clinical trials, announced the successful completion of the first phase of a big data research project to develop novel algorithms for the automated analysis of medical images in clinical trials. This work was made possible by a strategic partnership with the Center for Dynamic Data Analytics (CDDA), a National Science Foundation (NSF) sponsored cooperative research center focused on developing scalable methods for handling large amounts of complex industry-related data. The BioClinica-CDDA project is part of the 'National Big Data and Research and Development Initiative', aimed at addressing the challenges and opportunities of 'Big Data' and is highlighted by the Obama Administration as a high-impact collaboration promoting "Data to Knowledge to Action."
Under the research project entitled 'Quantitative Tissue Assessment', scientific experts from BioClinica and Rutgers University worked together to define, direct and develop important quantitative tools for the clinical assessment of new therapies for muscle, liver and spleen diseases. These tools enable the extraction of quantitative data from medical images with increased automation and precision. The quantification of muscle tissue is becoming an increasingly important measurement in aging populations for assessing sarcopenia and other musculoskeletal diseases. Additionally, tools for the evaluation of liver and spleen are needed for clinical trials for non-alcoholic steato-hepatitis (NASH) and for a number of orphan diseases.
"These types of advances are the first steps in the application of big data that are being brought to bear on the diagnosis and development of new drugs in areas of unmet medical need" said Colin Miller PhD, Senior Vice President of Medical Affairs at BioClinica. The methods developed here will be put into production to facilitate the analysis of large imaging datasets that arise from ongoing global, multi-site clinical trials. "The Quantitative Tissue Assessment project underscores BioClinica's commitment to innovation in medical imaging" added David S. Herron, Executive Vice President at BioClinica and President of the company's Imaging Core Lab Division. "We are excited to partner with the CDDA on these strategic projects which have the potential to revolutionize big data computing for medical imaging."
On the heels of the success of the 'Quantitative Tissue Assessment' project, BioClinica and the CDDA have additional projects in the works, including the development of scalable algorithms for automated image analysis for additional therapeutic areas and unmet medical needs.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services including electronic transfer, management, and independent review of medical images; cardiovascular safety monitoring including automated ECG, Thorough QT studies, Holter monitoring, ambulatory blood pressure monitoring and pulse wave analysis; and eClinical solutions for electronic data capture, randomization, clinical trial management, and clinical supply chain forecasting and optimization. BioClinica offers unmatched scientific expertise with a team of respected medical researchers and board certified sub-specialty trained radiologists, cardiologists, nuclear medicine physicians and oncologists. With more than 28 years of experience and over 3000 successful trials to date, BioClinica has supported the development of many new medicines through all phases of the clinical trial process. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide comprehensive cardiovascular safety, and eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.
|SOURCE BioClinica, Inc.|
Copyright©2012 PR Newswire.
All rights reserved